SCHEMBL4674471

SCHEMBL4674471

Cc1ccc(Cc2ccoc2C(=O)/C=C(\O)C(=O)O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.37
ATM Q13315 2/20 0.36
TDP1 Q9NUW8 4/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
HSD17B10 Q99714 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KMT2A Q03164 2/20 0.34
CTBP2 P56545 1/20 0.34
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
ESR1 P03372 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
APEX1 P27695 1/20 0.33
MAPK1 P28482 1/20 0.33
ESR2 Q92731 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674473 1.00 SRD5A2 (0.37) SRD5A2ATMTDP1L3MBTL1HSD17B10
SCHEMBL4674462 0.89 KMT2A (0.40) L3MBTL1KMT2APOLBGPR52
SCHEMBL4674464 0.89 KMT2A (0.40) L3MBTL1KMT2APOLBGPR52
SCHEMBL4672737 0.87 LMNA (0.48) L3MBTL1HSD17B10SMN1; SMN2KMT2A
SCHEMBL4672735 0.87 LMNA (0.48) L3MBTL1HSD17B10SMN1; SMN2KMT2A
SCHEMBL4670571 0.86 ITGB1 (0.35) TDP1KMT2AMEN1
SCHEMBL4675595 0.86 ALDH1A1 (0.36) L3MBTL1KMT2ACTBP2KDM4EMEN1
SCHEMBL4670573 0.86 ITGB1 (0.35) TDP1KMT2AMEN1
SCHEMBL4675592 0.86 ALDH1A1 (0.36) L3MBTL1KMT2ACTBP2KDM4EMEN1
SCHEMBL4674429 0.86 LTA4H (0.42) ATMTDP1L3MBTL1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SRD5A2 371/4885ATM 3662/4885TDP1 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.